[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636674":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":23,"studyPopulation":23,"armGroups":30,"interventions":37,"overallOfficials":42,"centralContacts":47,"locations":55,"responsibleParty":72,"collaborators":75,"id":79,"slug":23,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":23,"eligibilityCriteria":83,"healthyVolunteers":80,"sex":84,"minAge":85,"maxAge":23,"enrollmentInfo":86,"targetDuration":23,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":23,"overallStatus":96,"whyStopped":23,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of California, Irvine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Flotufolastat F18 PET findings","Compare Flotufolastat F18 PET findings to mpMRI and MRI-fusion biopsy results to determine successful treatment by focal therapy.","5 years",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Changes in Circulating Tumor Deoxyribonucleic acid (ctDNA) levels","Changes between timepoints in circulating tumor deoxyribonucleic acid (ctDNA) from baseline (pre-therapy) to the defined post-therapy timepoint.",{"measure":18,"description":19,"timeFrame":12},"Changes in PSA levels","Changes between timepoints in PSA from baseline (pre-therapy) to the defined post-therapy timepoint.",{"measure":21,"description":22,"timeFrame":12},"Change in genomic assay scores","Change in genomic assay scores as measured using each assay's validated soring system from baseline (pre-therapy) to the defined post-therapy timepoint.",null,{"allocation":25,"interventionModel":26,"interventionModelDescription":23,"primaryPurpose":27,"observationalModel":23,"timePerspective":23,"maskingInfo":28},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":29,"maskingDescription":23,"whoMasked":23},"NONE",[31],{"label":32,"type":33,"description":34,"interventionNames":35},"Post-Focal Therapy Flotufolastat F18PET","EXPERIMENTAL","Post-Focal Therapy Flotufolastat F18 PET",[36],"Diagnostic Test: Flotufolastat F18 PET",[38],{"type":39,"name":40,"description":40,"armGroupLabels":41,"otherNames":23},"DIAGNOSTIC_TEST","Flotufolastat F18 PET",[32],[43],{"name":44,"affiliation":45,"role":46},"Michael Daneshvar, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[48,53],{"name":49,"role":50,"phone":51,"phoneExt":23,"email":52},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":54,"role":50,"phone":23,"phoneExt":23,"email":23},"University of California Irvine Medical Center",[56],{"facility":57,"status":23,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Chao Family Comprehensive Cancer Center, University of California, Irvine","Orange","California","92868","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-117.85311,33.78779,{"lat":67,"lon":66},[70],{"name":44,"role":50,"phone":71,"phoneExt":23,"email":52},"877-827-8839",{"type":46,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Michael Daneshvar","Assistant Professor of Clinical Urology",[76],{"name":77,"class":78},"Blue Earth Diagnostics","INDUSTRY","100636674",false,"NCT07568756","Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation","Inclusion Criteria:\n\n* Age 18 years or greater at time of consent\n* Prostate adenocarcinoma (no other histologic subtypes allowed)\n* Prostate Cancer planned to be treated by focal therapy (e.g. cryotherapy, HIFU, or NanoKnife)\n* Multiparametric-MRI imaging planned\n* Planned pre- and post- treatment MRI-fusion biopsy\n\nExclusion Criteria:\n\n* Prior treatment for any prostate malignancy (e.g. radiation, focal therapy, or systemic therapy)\n* Genomic classifiers (e.g. Decipher) signifying intermediate or high-risk disease\n* PSA \\>10\n* High-risk prostate cancer (diagnosed by biopsy)\n* Bilateral prostatic lobe disease","MALE","18 Years",{"count":87,"type":88},60,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","This is a phase II single arm, open-label clinical trial determining diagnostic accuracy of Flotufolastat F18 PET in subjects with prostate adenocarcinoma. These are subjects who have not previously received treatment for prostate cancer.",[94,95],"Prostate Adenocarcinoma","Prostate Cancer","NOT_YET_RECRUITING","2026-04-28",{"date":99,"type":100},"2026-05-06","ACTUAL",{"date":102,"type":88},"2026-05",{"date":104,"type":88},"2029-05",{"name":5,"class":6},1]